High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- JPMorgan revealed Friday that it has started coverage of Hims & Hers Health at Neutral, setting a December 2027 price target of $32 as it weighs the direct-to-consumer health platform's rapid growth against execution risks in its shift to branded weight-loss drugs.
Wobbly start predicted Stock futures wobbled on Tuesday morning as investors weighed the fallout from the weekend's escalation in Iran, a jittery bond market and the growing chance the Fed might hike rates again. Dow and S&P 500 futures slipped around 0.5%, while Nasdaq-100 contracts...
Andrew Dudum told CNBC the agency wanted "more of a headline than a real agreement" after years of cooperative talks
Investing.com -- Hims & Hers Chief Executive Andrew Dudum defended the telehealth company against a Federal Trade Commission lawsuit concerning its data sharing practices in an interview that aired Tuesday on CNBC's "Squawk Box."
Subscriber growth accelerated as revenue surged 38% and international expansion took off.
By Amina Niasse NEW YORK, Aug 12 (Reuters) - Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's
HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.
Hims & Hers Health raised its 2026 revenue outlook to between $3.1 billion and $3.3 billion from its earlier guidance between $2.8 billion and $3 billion.
Hims & Hers raises its 2026 revenue outlook as AI boosts engagement, specialty care expands and Eucalyptus extends its international reach despite margin pressure.
Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here’s what to expect.
The telehealth company posted a net loss of $86.3 million in the second quarter while raising its full-year revenue outlook to $3.1–$3.3 billion
Aug 11 (Reuters) - Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, as concerns over shrinking profit margins overshadowed strong subscriber growth and a raised annual revenue forecast. The company posted second-quarter revenue on Monday that topped expectations and added more than 300,000 subscribers.
Strong subscriber growth and international expansion drive record performance, offset by margin pressures and FTC legal challenges.
Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally. Chief Financial Officer Yemi Okupe said dome
Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year. Madison Muller reports on "Bloomberg The Close."
Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications.
The telehealth platform said it now projects $3.1 billion to $3.3 billion in revenue for the year, up from a previous target for $2.8 billion to $3 billion.
NEW YORK, Aug 10 (Reuters) - Hims & Hers Health on Monday posted second-quarter revenue above estimates and raised its annual revenue forecast, as the telehealth company benefited from an increase in
This week, we pivot to "Inflation Week," with Wednesday and Thursday morning bringing new monthly price index data.
Monday Earnings (a.m): Barrick Mining Earnings (p.m.): Simon Property, Rocket Lab, JBS, Hims & Hers Health, Trump Media Tuesday Economic data: NFIB small-business index for July, existing home sales Earnings: Cardinal Health, Lumentum, CoreWeave, Super Micro, On Holding, Smithfield Foods Wednesday Inflation data: Consumer price index for July, 8:30 a.
SharkNinja (NYSE:SN) reported second-quarter 2026 results marked by accelerating sales growth, higher adjusted earnings and a raised full-year outlook, as the company cited broad demand across domestic and international markets, product categories and sales channels. Net sales increased 22.2% year
Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doust
Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr
Clover Health Investments (NASDAQ:CLOV) reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures. Chief Executive Officer Andrew Toy said the company views its Clove
Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.
Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.
According to the suit, Hims & Hers shared lists of certain customers, and the actions of visitors on its website, with advertisers such as Meta and Snap, even though it claimed its service maintains consumers’ privacy.
The U.S. Federal Trade Commission on Wednesday sued the telehealth company over allegations it shared sensitive user health data with advertisers.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
